Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Mar 3;8(3):e252008.
doi: 10.1001/jamanetworkopen.2025.2008.

Older Adults' Views on Insurance Coverage for Weight Management Medications

Lauren Oshman  1   2 , Matthias Kirch  2 , Erica Solway  2 , Dianne C Singer  2 , Preeti N Malani  2   3   4 , J Scott Roberts  2   5 , Jeffrey T Kullgren  2   4   6   7 , Dina Hafez Griauzde  2   7   8
Affiliations

Older Adults' Views on Insurance Coverage for Weight Management Medications

Lauren Oshman et al. JAMA Netw Open. .

Abstract

Importance: Medicare and many commercial insurers do not cover US Food and Drug Administration-approved weight management medications, such as incretin mimetics (semaglutide, tirzepatide, and liraglutide), bupropion-naltrexone, and phentermine-topiramate).

Objectives: To assess older adults' interest in weight management medications and associated characteristics and to understand their perceptions about insurance coverage of weight management medications.

Design, setting, and participants: This survey study used cross-sectional data from a nationally representative sample of US adults ages 50 to 80 years from the July 2023 National Poll on Healthy Aging. Data were analyzed from August to November 2023.

Main outcomes and measures: Outcomes of interest were estimates of interest in taking weight management medication and perceptions about coverage for US Food and Drug Administration-approved weight management medications by insurers, including Medicare.

Results: Among 2657 respondents, 60.3% (95% CI, 56.7%-63.8%) were ages 50 to 64 years, 52.2% (95% CI, 49.8%-54.5%) were female, and 10.6% (95% CI, 9.3%-12.0%) were non-Hispanic Black, 11.4% (95% CI, 10.4%-12.6%) were Hispanic, and 70.3% (95% CI, 68.2%-72.4%) were non-Hispanic White. Overall, 35.1% (95% CI, 31.9%-38.4%) of participants were interested in using weight management medications, including 59.1% (95% CI, 53.4%-64.5%) of individuals with body mass index (BMI) of 30 or greater. Interest was most robustly associated with having used these medications in the past (adjusted odds ratio, 7.57 [95% CI, 4.41-13.02]) and BMI of 30 or greater (adjusted odds ratio, 5.04 [95% CI, 3.48-7.30]). Most participants (of any BMI) agreed that health insurance should cover weight management medications (2176 of 2625 respondents [83.2%]). When asked whether Medicare should cover such medications, most still favored coverage (2097 of 2616 respondents [75.7%]), but fewer approved of paying more for a Medicare premium to ensure coverage (829 of 2604 respondents [30.2%]).

Conclusions and relevance: In this survey study of older US adults, most participants agreed that Medicare should cover weight management medications and more than half of those with BMI of 30 or greater were interested in using them. These results should inform decisions to include weight management medications in the Medicare and commercial insurance programs, as well as utilization policies to control health care costs.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Oshman reported owning stock in Merck Stock, AbbVie, Eli Lilly, and Abbott Laboratories outside the submitted work. Dr Kullgren reported Dr Kullgren reported receiving grants from the National Institutes of Health, US Department of Veterans Affairs, American Diabetes Association, Robert Wood Johnson Foundation, Donaghue Foundation, Healthwell Foundation, State of Michigan Department of Military and Veterans Affairs, and Michigan Health Endowment Fund; personal fees from SeeChange Health, HealthMine, Kaiser Permanente Washington Health Research Institute, Washington State Office of the Attorney General, Robert Wood Johnson Foundation, AbilTo, Kansas City Area Life Sciences Institute, American Diabetes Association, Luxembourg National Research Fund, Donaghue Foundation, National Science Foundation, University of California, Los Angeles, University of Pennsylvania, Oak Ridge Associated Universities, and the University of Southern California outside the submitted work. Dr Griauzde reported receiving grants from National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases during the conduct of the study and personal fees from Blue Cross Blue Shield of Michigan and National Kidney Foundation of Michigan outside the submitted work. No other disclosures were reported.

References

    1. Ward ZJ, Bleich SN, Cradock AL, et al. . Projected U.S. state-level prevalence of adult obesity and severe obesity. N Engl J Med. 2019;381(25):2440-2450. doi:10.1056/NEJMsa1909301 - DOI - PubMed
    1. Guh DP, Zhang W, Bansback N, Amarsi Z, Birmingham CL, Anis AH. The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. BMC Public Health. 2009;9(1):88. doi:10.1186/1471-2458-9-88 - DOI - PMC - PubMed
    1. Ward ZJ, Bleich SN, Long MW, Gortmaker SL. Association of body mass index with health care expenditures in the United States by age and sex. PLoS One. 2021;16(3):e0247307. doi:10.1371/journal.pone.0247307 - DOI - PMC - PubMed
    1. Milken Institute . Weighing down America: 2020 update. Accessed September 3, 2024. https://milkeninstitute.org/content-hub/research-and-reports/reports/wei...
    1. Williamson DA, Bray GA, Ryan DH. Is 5% weight loss a satisfactory criterion to define clinically significant weight loss? Obesity (Silver Spring). 2015;23(12):2319-2320. doi:10.1002/oby.21358 - DOI - PubMed

Publication types

Substances